Literature DB >> 23382112

New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma.

Riccardo Lencioni1.   

Abstract

The modified Response Evaluation Criteria in Solid Tumors (mRECIST) guideline has introduced specific amendments to standard RECIST to address the unique complexities involved in the evaluation of tumor response in hepatocellular carcinoma. A growing amount of data suggests that mRECIST, designed for response assessment in clinical trials, may translate into a tool for clinical practice.

Entities:  

Mesh：

Year:  2013        PMID： 23382112     DOI： 10.1158/1078-0432.CCR-12-3796

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  31 in total

1.  Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis.

Authors:  Julius Chapiro; Laura D Wood; MingDe Lin; Rafael Duran; Toby Cornish; David Lesage; Vivek Charu; Rüdiger Schernthaner; Zhijun Wang; Vania Tacher; Lynn Jeanette Savic; Ihab R Kamel; Jean-François Geschwind
Journal:  Radiology       Date:  2014-07-15       Impact factor: 11.105

2.  Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5.

Authors:  Jun Dong; Wang Li; Annan Dong; Siyue Mao; Lujun Shen; Sheng Li; Xiao Gong; Peihong Wu
Journal:  Med Oncol       Date:  2014-07-03       Impact factor: 3.064

3.  MRI-Based Radiomics: Nomograms predicting the short-term response after transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma patients with diameter less than 5 cm.

Authors:  Yani Kuang; Renzhan Li; Peng Jia; Wenhai Ye; Rongzhen Zhou; Rui Zhu; Jian Wang; Shuangxiang Lin; Peipei Pang; Wenbin Ji
Journal:  Abdom Radiol (NY)       Date:  2021-03-13

4.  Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study.

Authors:  Tongchun Xue; Fan Le; Rongxin Chen; Xiaoying Xie; Lan Zhang; Ningling Ge; Yi Chen; Yanhong Wang; Boheng Zhang; Shenglong Ye; Zhenggang Ren
Journal:  Med Oncol       Date:  2015-02-15       Impact factor: 3.064

Review 5.  Interventional Oncology in Hepatocellular Carcinoma: Progress Through Innovation.

Authors:  Lin Mu; Julius Chapiro; Jeremiah Stringam; Jean-François Geschwind
Journal:  Cancer J       Date:  2016 Nov/Dec       Impact factor: 3.360

6.  Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis.

Authors:  C Floridi; F Pesapane; S A Angileri; D De Palma; F Fontana; F Caspani; A Barile; A Del Sole; C Masciocchi; G Lucignani; G Carrafiello
Journal:  Med Oncol       Date:  2017-09-05       Impact factor: 3.064

7.  Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.

Authors:  Vania Tacher; MingDe Lin; Rafael Duran; Hooman Yarmohammadi; Howard Lee; Julius Chapiro; Michael Chao; Zhijun Wang; Constantine Frangakis; Jae Ho Sohn; Mitchell Gil Maltenfort; Timothy Pawlik; Jean-François Geschwind
Journal:  Radiology       Date:  2015-07-01       Impact factor: 11.105

Review 8.  New concepts in embolotherapy of HCC.

Authors:  F Pesapane; N Nezami; F Patella; J F Geschwind
Journal:  Med Oncol       Date:  2017-03-16       Impact factor: 3.064

9.  Dual-balloon infusion microcatheter for selective drug-eluting bead transarterial chemoembolization: initial feasibility study.

Authors:  Wayne L Monsky; Siddharth A Padia; Andrew Hal Hardy
Journal:  Diagn Interv Radiol       Date:  2017 Nov-Dec       Impact factor: 2.630

10.  Imbalance in systemic inflammation and immune response following transarterial chemoembolization potentially increases metastatic risk in huge hepatocellular carcinoma.

Authors:  Tong-Chun Xue; Qing-An Jia; Ning-Ling Ge; Yi Chen; Bo-Heng Zhang; Sheng-Long Ye
Journal:  Tumour Biol       Date:  2015-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.